US Bancorp DE Raises Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

US Bancorp DE lifted its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 0.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,680 shares of the medical research company’s stock after buying an additional 87 shares during the period. US Bancorp DE’s holdings in Bio-Rad Laboratories were worth $3,180,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Bio-Rad Laboratories by 1.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 441,098 shares of the medical research company’s stock worth $147,583,000 after buying an additional 4,260 shares during the period. Westfield Capital Management Co. LP boosted its position in shares of Bio-Rad Laboratories by 3.9% in the third quarter. Westfield Capital Management Co. LP now owns 252,769 shares of the medical research company’s stock worth $84,571,000 after buying an additional 9,584 shares during the period. Point72 Asset Management L.P. purchased a new stake in shares of Bio-Rad Laboratories in the third quarter worth about $83,681,000. Mawer Investment Management Ltd. boosted its holdings in Bio-Rad Laboratories by 63.0% in the third quarter. Mawer Investment Management Ltd. now owns 217,885 shares of the medical research company’s stock valued at $72,900,000 after purchasing an additional 84,237 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in Bio-Rad Laboratories by 15.2% in the fourth quarter. Fisher Asset Management LLC now owns 106,871 shares of the medical research company’s stock valued at $35,108,000 after purchasing an additional 14,135 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Analyst Ratings Changes

BIO has been the subject of a number of analyst reports. Wells Fargo & Company reduced their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a report on Wednesday, February 12th. StockNews.com downgraded Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, Bio-Rad Laboratories presently has an average rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Trading Down 0.8 %

Shares of NYSE BIO opened at $258.37 on Friday. The stock’s 50 day moving average price is $322.58 and its two-hundred day moving average price is $331.14. Bio-Rad Laboratories, Inc. has a 52-week low of $248.22 and a 52-week high of $387.99. The stock has a market capitalization of $7.24 billion, a P/E ratio of -3.97 and a beta of 0.90. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. On average, analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.